Artelo Biosciences

Contributing Author

Recent Articles by Artelo Biosciences

Oct-01	Artelo Biosciences Announces Closing of $2.0 Million Public Offering ARTL GlobeNewswire
Sep-30	Artelo Biosciences Announces Pricing of $2.0 Million Public Offering ARTL GlobeNewswire
Sep-29	Artelo Biosciences Announces Proposed Underwritten Public Offering ARTL GlobeNewswire
Sep-29	Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference ARTL GlobeNewswire
Sep-10	Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms ARTL GlobeNewswire
Sep-05	Artelo Biosciences Announces Closing of $3.0 Million Public Offering ARTL GlobeNewswire
Sep-04	Artelo Biosciences Announces Pricing of $3.0 Million Public Offering ARTL GlobeNewswire
Sep-03	Artelo Biosciences Announces Proposed Underwritten Public Offering ARTL GlobeNewswire
Sep-03	Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results ARTL GlobeNewswire
Sep-03	Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) ARTL GlobeNewswire
Aug-25	Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain ARTL GlobeNewswire
Aug-13	Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results ARTL GlobeNewswire
Aug-11	Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 ARTL GlobeNewswire
Aug-04	Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset ARTL GlobeNewswire
Aug-01	Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression ARTL GlobeNewswire
Jul-09	Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium ARTL GlobeNewswire
Jul-07	Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model ARTL GlobeNewswire
Jun-30	Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain ARTL GlobeNewswire
Jun-26	Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing ARTL GlobeNewswire
Jun-11	Artelo Biosciences Announces Reverse Stock Split ARTL GlobeNewswire
Jun-05	Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study ARTL GlobeNewswire
Jun-02	New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression ARTL GlobeNewswire
May-13	Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results ARTL GlobeNewswire

Artelo Biosciences

Recent Articles by Artelo Biosciences

Upgrade your FINVIZ experience